Kornimate/medical-research-clean huggingface dataset:
factors associated with quality of dreams during general anesthesia

Conditions: Dream; General Anesthesia; Perioperative Factors; Depression

Summary: patients frequently report having dreams during general anesthesia. the incidence of dreams during general anesthesia that have been reported by patients upon awakening has been reported to range from 10 to 36% \[1\] and to be higher in younger patients, female patients \[2\], and patients who received ketamine \[3\]. the quality of dreams during general anesthesia is often reported as pleasant, but some patients report unpleasant or not pleasant dreams \[4, 5\]. however, the factors associated with the quality of dreams have remained to be elucidated. therefore, the aim of this study was to determine the relationships between the quality of dreams during general anesthesia and perioperative factors.


Eligibility criteria:
inclusion criteria: * we recruited patients who were more than 20 years of age * patients who were scheduled for elective surgery under general anesthesia regardless of the type of surgery exclusion criteria: * diagnosis of a psychological disorder, * major afective disorder * major drug dependence disorder, * inability to understand the content of our study, * planned postoperative ventilation, * anticipation of unavailability for postoperative interviews
hämeenlinna metabolic syndrome research program: effects of rapeseed oil on serum lipids and platelet function

Conditions: Metabolic Syndrome

Summary: in this study, the effects of dietary intake of cold-pressed turnip rapeseed oil (ctpro) and milk fat are compared in men with metabolic syndrome having already participated in hms-02 study.

this open and balanced cross-over study consists of two dietary treatment phases (either virgino (r) ctpro or butter) for 6 to 8 weeks. they are separated from each other with an eight-week washout period. at the end of both periods and 12-hour fasting an oral glucose-fat tolerance test is carried out. except glucose, the test consists cream (after the butter phase) and ctpro (after the ctpro phase). otherwise, the subjects (n=43) are asked to maintain their normal dietary habits.

Eligibility criteria:
inclusion criteria: * 43 men with metabolic syndrome having already participated in the hms-02 study * willing to participate in a demanding dietary study exclusion criteria:

Keywords: dietary cross-over study lipids rapeseed oil butter milk fat unsaturated fat saturated fat oxidized ldl platelet function arterial elasticity
effect of erythropoietin on neurodevelopmental outcomes in very preterm infants with intraventricular hemorrhage

Conditions: Premature Infants

Summary: erythropoietin (epo) has been shown to be neurotrophic and neuroprotective in several animal models and some clinical studies. our hypothesis is that epo could improve long-term neurological outcomes in very preterm infants with intraventricular hemorrhage (ivh). the aim of this study is to evaluate the long-term neuroprotective effect of repeated low-dose epo (500 u/kg) in very preterm infants with ivh.

ivh is one of the most common complications in preterm infants. nearly 60% of preterm infants with grade iii-iv ivh develop severe neurodevelopmental outcomes. there are currently no effective treatments to prevent preterm infants with ivh from developing ventricular dilation or serious neurological disabilities. recent studies have shown that epo could improve neurodevelopmental outcomes in preterm infants with grade iii-iv ivh. however, the dose and course of epo in preterm infants is still uncertain. the purpose of the study was whether repeated low-dose epo (500 u/kg, every other day, for 2 weeks) given to very preterm right after the diagnosis of ivh could improve long-term neurological outcomes. very preterm infants with gestational age of ≤ 32 weeks who are diagnosed with ivh within 72 hours after birth in nicu are eligible for enrolment. after informed consent is obtained, infants will be randomly assigned to epo group or vehicle group. the primary outcome is whether epo improves mortality and neurological disabilities in very preterm infants with ivh at 18 months of corrected age, and the secondary outcome was whether epo decrease the incidence of cerebral palsy, mdi\<70, blindness, and deafness.

Eligibility criteria:
inclusion criteria: * preterm infants admitted to nicu ≤ 32 weeks gestation at birth * birth weight less than 1500 g * less than 72 hours of life at time of enrolment * diagnosed as ivh by head ultrasound * written informed consent of parent or guardian exclusion criteria: * genetic metabolic diseases * congenital abnormalities * polycythaemia (hct \> 65%) within first 24 hours of life * thrombocytopenia (platelets \< 50k cells/microl) within first 24 hours of life * unstable vital signs (such as respiration and circulation failure)
droplet-digital pcr for the detection of circulating cell-free dna in patients with cystic echinococcosis: an exploratory study

Conditions: Cystic Echinococcosis

Summary: it is an experimental study, multicentre, non-profit, whose aim is to preliminarily evaluate the sensitivity of ddpcr for the detection of cfdna in the diagnosis of cystic echinococcosis and to generate data for its potential use also for the discrimination of the presence of infection with active/inactive cysts and the post-therapy follow-up.

it is an experimental study, multicentre, non-profit, whose aim is to preliminarily evaluate the sensitivity of ddpcr for the detection of cfdna in the diagnosis of cystic echinococcosis and to generate data for its potential also use for discrimination of the presence of infection with active/inactive cysts and follow-up aftercare, to be explored in subsequent studies. for this purpose, the plasma of adult patients with untreated hepatic cystic echinococcosis will be analysed. the analyzes will be carried out on samples of patients who have already had a definitive diagnosis of cystic echinococcosis, and therefore the results of the study analyzes will have no influence on the diagnosis and clinical management of the patient, which, therefore, will not be informed of the result of the analyzes relating to his/her sample.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years; 2. definite diagnosis of hepatic cystic echinococcosis, ascertained on the basis of the presence of at least one liver cyst with pathognomonic signs on ultrasound examination or the presence of at least one liver cyst without clearly visible pathognomonic signs but presence of positive serology with at least two validated commercial tests or western blot (ldbio diagnostics, lyon, france) positive for anti-echinococcus antibodies (who-iwge diagnostic criteria, brunetti et al 2010); 3. no prior therapy for cystic echinococcosis reported; 4. willingness to participate in the study by signing the informed consent form. exclusion criteria: 1. age \< 18 years; 2. unconfirmed diagnosis of cystic echinococcosis; echino_ddpcr version 1.1 of 02/14/2022 3. presence of echinococcal cysts only in extra-hepatic localization; 4. history of treatment for cystic echinococcosis.
effectiveness of motivational interview in patients with dyslipidemia

Conditions: Patients With Dyslipidemia

Summary: evaluate the effectiveness of motivational interviewing to improve lipid control and cardiovascular risk in patients with dyslipidemia.


Eligibility criteria:
inclusion criteria: * people diagnosed with dyslipidemia * to sign informed consent. exclusion criteria: * secondary hypercholesterolemia. * familial hypercholesterolemia. * deficiency syndromes family high density lipoprotein. * subjects with a history of cardiac or cerebrovascular events. * other chronic health problems such as diabetes or severe copd. * subjects with current diagnosis of cancer. * patients with hepatic or renal disorders . * subjects heavy drinkers. * patients with long standing sick leave (more than 6 months). * pregnant or breastfeeding.

Keywords: dyslipidemia, motivational interview, prevention
(pekk) framework for mandibular implant-supported complete fixed prostheses

Conditions: Bone Loss; Peri-Implantitis

Summary: this clinical study aims to evaluate the effect of using pekk (pekkton) framework in mandibular implant-supported complete fixed dental prostheses with all-on-four treatment concept on peri-implant tissues health

the aim of this clinical study is to evaluate the effect of using pekk (pekkton) framework in mandibular implant-supported complete fixed dental prostheses with all-on-four treatment concept on peri-implant tissues health regarding the following parameters: * modified plaque index * modified gingival index * peri-implant probing pocket depth radiographic evaluation (periapical x-ray): marginal bone height changes

Eligibility criteria:
inclusion criteria: * maxillary and mandibular alveolar ridges were covered with healthy, firm, relatively even thickness and even compressible mucosa and free from any signs of inflammation or flabbiness. * patients had completely edentulous maxillary and mandibular ridges with sufficient mandibular bone height not less than 15 mm in the interforaminal area and at least 12mm posteriorly * all patients had sufficient inter-arch space * all patients complained of insufficient retention and stability of their conventional mandibular dentures. * all patients were of angel's class i maxillo-mandibular relationship. exclusion criteria: * patients with absolute contraindications for implant placement, such as active cancer and diseases of the immune system. * patients with metabolic diseases that are directly related to bone resorption, such as uncontrolled diabetes, osteoporosis, and hyperparathyroidism. * patients with general contraindications for surgical procedures, such as hematologic diseases, hepatic patients, patients with bleeding disorders, and serious problems with coagulation. * patients with a history of irradiation of the head and neck region or chemotherapy in the last 3 years were also excluded. * patients with relative contraindications such as a history of parafunctional habits (such as bruxism and clenching), smoking, alcoholism, and patients with any physical reasons that could affect follow-up. * patients with local contraindications for implant placement, such as localized bone defects.
a study of an existing database to assess the treatment persistence to basal insulin in type 2 diabetes mellitus patients in a structured patient education program in india

Conditions: Type 2 Diabetes Mellitus (T2DM)

Summary: the aim of this study is to analyze data from an existing database named saath-7 star, in order to assess the treatment persistence to basal insulin in type 2 diabetes patients who had been enrolled in the saath-7 star structured patient education program in india.

this retrospective study will involve secondary analysis of already existing data of indian t2dm patients who were administered subcutaneous injectable solutions of insulin glargine (lantus® or toujeo®), as per routine clinical practice and who were enrolled in a structured educational program named saath-7 star. six-months data for eligible patients, who were enrolled in the saath-7 star program during the index period of march 2019-august 2019, collected from the saath-7 star database will be analyzed for the defined objectives. the index date is defined as the date of enrollment in saath-7 star program i.e. 1st month, which will also be considered as the 'baseline'

Eligibility criteria:
inclusion criteria: * male or female aged ≥ 18 years * t2dm patients enrolled in saath-7 star program during the index period from march 2019 to august 2019 exclusion criteria: * type 1 diabetes patients * patients with gestational diabetes the above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
a genotype-phenotype urothelial cancer registry

Conditions: Urothelial Cancer; Renal Pelvis Cancer; Ureter Cancer; Bladder Cancer

Summary: this study is being done to create a registry to help us learn more about urinary and other cancers. this will let us look at large groups of people who do and do not have this kind of cancer. the investigators will look at risk factors to learn more about how these impact cancer. the investigators will also look at genetic markers. these are genes that are found in a known place. they are often associated with a particular trait. if the gene changes in some way, it may predict cancer or response to treatment. the investigators will look for markers in your saliva. this registry will help us develop better methods of: preventing these cancers. diagnosing these cancers. treating these cancers.


Eligibility criteria:
inclusion criteria: urothelial cancer cases * must be ≥ 18 years of age and * must have a diagnosis of urothelial cancer and * must be an english-speaker non-cancer control group * must be ≥ 18 years of age and * must not have cancer or a personal history of cancer, with the exception of skin cancer. and * must not be a blood relative of cases and * must not be a blood relative of another control and * must be an english-speaker family member control group: in select kindreds with a high prevalence of bladder cancer and/or very early onset bladder cancer, first- and second-degree family members of probands may be contacted by the mskcc study team and invited to complete the questionnaire and submit a saliva sample. * must be ≥ 18 years of age and * must be a blood relative of a case participant and * must be an english-speaker exclusion criteria: * have any condition, which in the opinion of the primary mskcc clinician or investigators precludes their ability to provide informed consent.

Keywords: renal pelvis ureter bladder 09-025 renal pelvis, ureter, bladder cancer
vitamin d3 for cgd patients with bcgosis/itis

Conditions: Vitamin D3; Chronic-granulomatous Disease; BCG

Summary: when children with chronic granulomatous disease (cgd) got bcg infection the treatment would be a tough task. the goal of the proposed research is to observe weather vitamin d supplementation can help the cgd children get through this challenge.

chronic granulomatous disease (cgd) is one of primary immunodeficiency diseases. due to the deficiency of the phagocyte nicotinamide adenine dinucleotide phosphate (nadph) oxidase the respiratory burst of all types of phagocytic cells is badly impaired which lead to a susceptibility to infection among cgd patients. bcg vaccine is wildly used in china to avoid severe tuberculosis infection. children are supposed to get bcg vaccine injected within 24 hours after birth. when patients with cgd got the vaccination of bcg they will easily got infected. and due to the immunodeficiency of these children, the infection cannot be cure by normal treatment. vitamin d supplementation was used to treat tuberculosis in the pre-antibiotic era and is reported to have influence on immune system especially on monocytes and macrophages thus may help cgd children defend the bcg infection. in addition, studies show that 1,25-dihydroxyvitamin d3 can induce nitric oxide synthase thus may up regulate no production and help host defense against human tuberculosis without the help of nadph oxidase. other researches indicate that vitamin d and the expression of vitamin d receptor may lead to induction of antimicrobial peptide such as ll-37 which help macrophages kill the intracellular mycobacterium tuberculosis. these discoveries indicated that vitamin d may induce immune response against bcg in a nontraditional way. therefore, when cgd patients face bcg infection, add vitamin d supplementation to the treatment may help them survive this challenge. since there have had clinical trials revealing that intermittent high dose vitamin d3 supplementation as 2.5mg per 14 days only receive positive effect on partial patients the investigators decide to choose a mild dose treatment as 800iu/d for 3 month to see if things get different in this way.

Eligibility criteria:
inclusion criteria: 1. less than 18 years' old 2. diagnosed with cgd 3. got bcg infection after vaccination exclusion criteria: 1. serum 25-(oh)-vit d \>75 nmol/l (30 ng/ml) 2. hyperphosphatemia 3. hypercalcemia 4. acute or chronic renal failure 5. acute or chronic cardiac failure 6. kidney stone
the chemopreventive effect of metformin in patients with familial adenomatous polyposis: double blinded randomized controlled study

Conditions: Familial Adenomatous Polyposis

Summary: familial adenomatous polyposis (fap) leads to adenomas and eventual adenocarcinomas in colon and less frequently, duodenum. chemopreventive strategies have been studied in fap patients to delay the development of adenomas and cancers. the non-steroidal anti-inflammatory drugs (nsaids) and selective cyclooxygenase-2 inhibitor have shown the regression of colorectal and duodenal adenomas in fap patients. however, these drugs showed gastrointestinal damage and cardiovascular risks, and new preventive strategies are needed. metformin, a biguanide, which is widely used for treating diabetes mellitus, has recently been suggested to have a suppressive effect on tumorigenesis via mtor-inhibiting pathway, and have no significant safety issues in long term use. the investigators devised a double-blind randomized controlled trial to evaluate the effect of metformin on polyps of colorectum and duodenum in non-diabetic fap patients.


Eligibility criteria:
inclusion criteria: 1. patients with familial adenomatous polyposis(fap) who are 20 to 65 years of age. 2. fap patients who have colonic or duodenal polyp 3. fap patients who have five or more polyps 2mm or more in diameter in endoscopic examination. exclusion criteria: 1. fap patients who had a history of colectomy within the previous 12 months or need to undergo colectomy within 8 months after randomization. 2. fap patients with malignant disease, including colorectal cancer. 3. fap patients who used nsaids (non-steroidal anti-inflammatory drugs) or aspirin three or more times a week within 6 months of randomization. 4. fap patients with diabetes mellitus. 5. pregnant or breast-feeding patients. 6. patients with abnormal results of serum laboratory tests (renal function and liver function test) and significant infectious or respiratory diseases.

Keywords: chemoprevention, metformin, familial adenomatous polyposis
a multimodal neuroimaging study of brain activation patterns under ketamine

Conditions: Major Depressive Disorder

Summary: the aim of the project is to establish a multimodal imaging approach for the investigation of the neural mechanisms underlying neuroreceptor regulation, glutamatergic metabolism and brain function that are of particular relevance for major depressive disorder (mdd) and that can be translated into clinical applications. there is growing evidence for imbalance with regard to glutamatergic neurotransmission in stress-related affective disorders. further support for the hypothesis that dysfunctional glutamatergic signaling underlies major depressive disorder, and indeed that its reversal constitutes a potential efficacious mechanism of action, is provided by the evidence that pharmacological compounds active at the n-methyl-d-aspartate (nmda) ionotropic glutamate receptor such as ketamine exert rapid antidepressant effects. as a tool compound ketamine enables the safe investigation of the brain region-specific effects of nmda receptor antagonism in terms of glutamatergic neurotransmission, brain function and the association of these neural changes with emotional state, thereby allowing for increased understanding of the therapeutic mechanism of action. the possibility to simultaneously study brain perfusion (arterial spin labeling), functional brain activity (fmri) and connectivity (resting state fmri), neurometabolism (proton magnetic resonance spectroscopy) and metabotropic glutamate receptor densities (positron emission tomography) will unravel their functional interplay in the mechanisms underlying the regulation of mood and cognition. combining those imaging modalities with treatment interventions in healthy subjects and depressed patients, this project aims at providing insight into the neuropharmacological effects of ketamine and its antidepressant properties.


Eligibility criteria:
inclusion criteria: * treatment resistant depressive episode * no restrictions regarding antidepressant medication exclusion criteria: * lifetime antidepressant treatment with ketamine * lifetime recreational use of ketamine * cardiovascular diseases such as hypertonia, cardiac insufficiency or myocardial infarct in the past six months * insufficiently treated anemia * hyper- or hypothyroidism * lifetime increased intracranial pressure or glaucoma * chronic physical diseases * hepatorenal dysfunction * any relevant psychiatric or neurological comorbidity, in particular dementia, epileptic seizures (lifetime), schizophrenia (lifetime), psychosis (lifetime), or post-traumatic stress disorder (current). * acute suicidality * substance abuse disorders * recent heart or head surgery * metallic body implants * agoraphobia * pregnancy * left handedness
motor intervention for preschooler with motor coordination deficits

Conditions: Developmental Coordination Disorder

Summary: this research project aims to examine the impact of motor coordination deficits and the effects of motor intervention on preschool-aged children's perceived competence, health-related physical fitness, activity participation and physical activity. eighty children, aged 4-6 years,with or without motor coordination deficits will be recruited and assigned to to motor intervention (dcd-t), control 1 (dcd-c) or control 2 (td) group. children in the intervention group will receive motor intervention for 12 weeks. all children will be assessed at baseline, 0-, 3- and 6-month post-intervention.

this research project aims to examine the impact of motor coordination deficits on preschool-aged children's perceived competence, health-related physical fitness, activity participation and physical activity. furthermore, the investigators are to investigate the effects of motor intervention on children's competence and participation during preschool age. this study plans to recruit 40 children with motor coordination deficits, aged 4-6 years, and 40 age- and gender-matched typically developing children. children with motor coordination deficits will further be randomly assigned to motor intervention (dcd-t) or control (dcd-c) group. at baseline assessment, all children will be assessed for motor coordination competence, self-perception of competence, health-related physical fitness and daily activity participation. physical activity will also be quantitatively measured using accelerometry. during the intervention phase, children in the dcd-t group will receive task-oriented motor intervention combined with fitness training three times per week while children in the dcd-c group remain usual activities. all children will be re-assessed at 0-, 3- and 6-month post-intervention. repeated measures anova will be applied to examine the differences of motor competence, self-perception, fitness and activity participation among the 3 groups of children and over the 9-month period. the effects of motor intervention on dcd children's competence and participation will also be examined.

Eligibility criteria:
inclusion criteria: * aged 4 to 6 years * motor coordination competence \ 30%ile for healthy group exclusion criteria: * genetic and chromosome deficits * neurological or neuromuscular disorders * congenital musculoskeletal disorders * fracture in the past 6 months * other conditions that affect the child's participation in physical activities